Published • loading... • Updated
Pharmaceutical Giant to Invest $6B in Alabama Facility
Lilly will create 450 permanent jobs and 3,000 construction jobs to boost supply chain resilience and local economic activity, expecting $4 in economic output per dollar invested.
- Eli Lilly and Company announced Tuesday it will invest more than $6 billion in a manufacturing facility at Greenbrier South industrial park, Huntsville, Alabama, with work starting in 2026 and completion in 2032.
- The company said the investment is part of a broader push to onshore API production, following a February plan to spend at least $27 billion on four U.S. plants.
- Lilly said production will include orforglipron and small-molecule synthetic and peptide ingredients while embedding machine learning, AI and digital automation for right-first-time execution.
- The company said the project will create 450 permanent jobs, 3,000 construction jobs, and generate up to $4 in local economic activity per dollar invested, boosting Huntsville's workforce.
- Lilly said proximity to the HudsonAlpha Institute for Biotechnology and utilities, transportation, favorable zoning and incentives drove Huntsville site selection, but the press release warned of risks affecting costs and timing, and a forthcoming site announcement is expected in the coming weeks.
Insights by Ground AI
57 Articles
57 Articles
Eli Lilly to build $6 billion drug production facility in Alabama
Lilly building $6 billion facility in Alabama Dec 9 (Reuters) – Indianapolis-based pharmaceutical giant Eli Lilly and Co. said on Tuesday it will invest more than $6 billion in a new active drug ingredient manufacturing facility in Huntsville, Alabama, to expand U.S. production and bolster medicine supply chains. The site, the third new U.S. facility announced by Lilly, will make small-molecule synthetic and peptide medicines, including orforgli…
·Indianapolis, United States
Read Full ArticleCoverage Details
Total News Sources57
Leaning Left6Leaning Right2Center19Last UpdatedBias Distribution70% Center
Bias Distribution
- 70% of the sources are Center
70% Center
L 22%
C 70%
Factuality
To view factuality data please Upgrade to Premium


















